Clinical risk factors in patients with interstitial lung disease associated with anti-MDA5 autoantibodies

Med Clin (Barc). 2023 Dec 22;161(12):515-522. doi: 10.1016/j.medcli.2023.07.013. Epub 2023 Aug 9.
[Article in English, Spanish]

Abstract

Introduction: The anti-MDA5-associated autoimmune disease represents a poorly understood entity. The study's objectives were to describe a cohort of interstitial lung disease (ILD) patients who were positive for anti-MDA5 autoantibody and identify clinical risk factors associated with survival.

Methods: This single-center cohort study included ILD patients positive for anti-MDA5 autoantibody. Baseline clinical features were registered, and survival analysis was performed to identify risk factors associated with worse survival.

Results: Fifty-three ILD-MDA5 positive patients were included; twelve died during follow-up due to rapidly progressive interstitial lung disease (RP-ILD). Dermatological signs of anti-MDA5 (Gottron papules, Gottron sign, palmar papules, V-neck sign, facial dermatomyositis rashes, and skin ulcers) were strongly associated with death secondary to RP-ILD (HR: 3.7, 95% CI: 1.02-13.35). Patients with dermatological signs were younger, had higher anti-MDA5 autoantibodies titers, more frequent inflammatory patterns in HRCT evaluation, and less fibrosis extent in HRCT.

Conclusion: Dermatological manifestation in ILD patients to anti-MDA5 autoantibodies are associated with RP-ILD and short-term fatal outcomes. Dermatological signs may identify a subgroup of ILD-positive to anti-MDA5 patients with a high risk of RP-ILD.

Keywords: Anti-MDA5; Enfermedad pulmonar intersticial; Inflammatory myopathies; Interstitial lung disease; Miopatías inflamatorias; Neumonía intersticial no específica; Nonspecific interstitial pneumonia.

MeSH terms

  • Autoantibodies*
  • Cohort Studies
  • Humans
  • Interferon-Induced Helicase, IFIH1
  • Lung Diseases, Interstitial* / complications
  • Lung Diseases, Interstitial* / etiology
  • Retrospective Studies
  • Risk Factors

Substances

  • Autoantibodies
  • Interferon-Induced Helicase, IFIH1